This report was recently updated on July 20 2024 with the latest and most recent
market numbers
Global Duchenne Muscular Dystrophy (DMD) Drugs Market Size, Trends & Analysis - Forecasts to 2026 By Therapeutic Approach (Mutation Suppression, Exon Skipping, and Steroid Therapy), By Product Type (Corticosteroids and Pain Management Drugs), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis
Duchenne muscular dystrophy (DMD) is affected by a defect or deficiency of the DMD gene, which functions for dystrophin, a central protein in the maintenance of structural integrity. It may, however, be inherited by parents or caused by a new mutation. Duchenne muscular dystrophy is a severe pediatric neuromuscular condition that causes muscle weakness and breakdown, resulting in trouble walking and overall reduced mobility. However, it mostly affects males since it is an X-linked genetic disease, though cases of females have also been recorded.
Drug researchers are now working on discovering novel treatments and therapies for newborns, premature children, and DMD patients in their final stages. The therapeutics for Duchenne muscular dystrophy has advanced rapidly in recent years, which has led to substantial growth in the Duchenne muscular dystrophy drugs market. However, owing to the high cost of treatments and medications, as well as a lack of understanding, a substantial percentage of people are now unable to benefit from them. The high cost of therapeutics continues to impede the expansion of the DMD drug landscape. However, policymakers in all major regions are implementing universal healthcare policies, which are influencing company price practices as well as the reimbursement scenario. Thus, boosting the global market for duchenne muscular dystrophy drugs.
The growing volume of duchenne muscular dystrophy cases is foreseen to drive the global duchenne muscular dystrophy treatment market throughout the forecast period. As per the National Organization for Rare Disorders, Duchenne muscular dystrophy affects 1 in every 3,500 male newborns globally. Furthermore, increased experimental testing for evaluating potential medications for Duchenne muscular dystrophy, as well as a diverse & upgrading drug portfolio, are presumed to fuel the global demand for duchenne muscular dystrophy therapy throughout the forecast period. For instance, five drug formulations are undergoing Phase 3 clinical trials for the management of duchenne muscular dystrophy: ataluren, casimersen, golodirsen, suvodirsen, and viltolarsen. The drug EXONDYS 51 was newly approved for the cure of this condition. Nevertheless, the worldwide duchenne muscular dystrophy drug demand is being held up by a reduced level of therapy as a result of the disease's deferral detection. Also, stringent legislative protocols and the absence of a structured process for determining therapeutic effectiveness are a few market growth constraints.
Growing investments in research and development to discover an appropriate cure for duchenne muscular dystrophy, as well as numerous awareness campaigns by organizations and government, are expected to boost the global market for duchenne muscular dystrophy treatment. Moreover, the advent of mutation-specific therapies is likely to fuel the global demand. Supportive insurance plans and federal measures in support of target-specific therapies are likely to further drive the demand throughout the forecast period.
So far, there are very few pharmacological medication drugs approved by the FDA for the diagnosis of duchenne muscular dystrophy. Thus, to increase the volume of FDA-approved drugs, various notable pharmaceutical companies are undertaking research projects and the proportion of such projects is foreseen to expand dramatically throughout the forecast period. Almost all prominent organizations are now focused on R&D operations, which would have an impact on the global market of duchenne muscular dystrophy drugs. Moreover, in recent years, there have been several technical breakthroughs that may help with testing processes and eventually lead to development in the global markets of duchenne muscular dystrophy drugs.
 drugs market.png)
Depending on the therapeutic approach, the market of duchenne muscular dystrophy (DMD) drugs is categorized as mutation suppression, exon skipping, and steroid therapy. Amongst these multiple interventions effective for duchenne muscular dystrophy, mutation suppression is foreseen to be the most favoured therapeutics. In duchenne muscular dystrophy, mutation suppressing therapy addresses the underlying gene that causes muscular dystrophy. Such medications contain Ataluren, a tiny compound discovered to inhibit nonsense mutations which aid dystrophic patients to skip the early stop codon and enable dystrophin formation. Furthermore, suppression therapy or nonsense mutation suppressing treatment has the ability to help a large number of patients recovering from duchenne. Meanwhile, several treatments are still being tested in clinical trials and many are on the threshold of being approved by the Food and Drug Administration (FDA). Thus, industry participants are focused on regular releases of mutation suppression innovation, which is a considerable variable boosting the segment and spurring market growth.
Based on the type of product, the market for Duchenne muscular dystrophy (DMD) drugs is classified as corticosteroids and pain management. Corticosteroids are likely to lead in this market since they are the only class of medications with demonstrated effectiveness in boosting muscle strength in the case of DMD. Moreover, Corticosteroids can reduce the risk of experiencing scoliosis, boost upper limb endurance, and aid in the maintenance of pulmonary and cardiovascular functionality during the non-ambulatory period of DMD.
 DRUGS MARKET.png)
As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central & South America. Due to novel drug advances, strong healthcare spending, and government outreach campaigns, North America leads the global duchenne muscular dystrophy market. Along with increasing disease occurrence and the imminent introduction of successful drug pipeline prospects, the United States has led the regional market and is expected to retain its position. The global market is presumed to expand due to an increase in clinical trials, particularly in the United States and Europe. Due to increased understanding of Duchenne muscular dystrophy and increased government and corporate health care policy coverage, the Asia Pacific market is foreseen to rise at a faster pace. Furthermore, this expansion is due to a surge in the introduction of new drugs as well as an uptick in the occurrence of Duchenne muscular dystrophy in the area.
Italfarmaco S.p.A., FibroGen, Inc., Summit Therapeutics Plc, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, Inc., NS Pharma, Inc., Wave Life Sciences, Daiichi Sankyo Company, Pfizer Inc., Solid Biosciences, among others, are the major players in the Duchenne muscular dystrophy (DMD) drugs market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview And Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Duchenne Muscular Dystrophy (DMD) Drugs Industry Overview, 2016-2026
2.1.1 Industry Overview
2.1.2 Therapeutic Approach Overview
2.1.3 Product Type Overview
2.1.4 Regional Overview
Chapter 3 Duchenne Muscular Dystrophy (DMD) Drugs Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2016-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Technology Advancement in Healthcare Industry
3.3.1.2 Increasing government funds.
3.3.2 Industry Challenges
3.3.2.1 Limited Study and Industry Participants
3.4 Prospective Growth Scenario
3.4.1 Therapeutic Approach Growth Scenario
3.4.2 Product Type Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Duchenne Muscular Dystrophy (DMD) Drugs Market, By Therapeutic Approach
4.1 Therapeutic Approach Outlook
4.2 Mutation Suppression
4.2.1 Market Size, By Region, 2016-2026 (USD Million)
4.3 Exon Skipping
4.3.1 Market Size, By Region, 2016-2026 (USD Million)
4.4 Steroid Therapy
4.4.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 5 Duchenne Muscular Dystrophy (DMD) Drugs Market, By Product Type
5.1 Product Type Outlook
5.2 Corticosteroids
5.2.1 Market Size, By Region, 2016-2026 (USD Million)
5.3 Pain Management Drugs
5.3.1 Market Size, By Region, 2016-2026 (USD Million)
Chapter 6 Duchenne Muscular Dystrophy (DMD) Drugs Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2016-2026 (USD Million)
6.2.2 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.2.3 Market Size, By Product Type, 2016-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.2.4.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.2.5.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2016-2026 (USD Million)
6.3.2 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.3.3 Market Size, By Product Type, 2016-2026 (USD Million)
6.3.4 Germany
6.2.4.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.2.4.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.3.5.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.3.6.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.3.7.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.3.8.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.3.9 Russia
6.3.9.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.3.9.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2016-2026 (USD Million)
6.4.2 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.4.3 Market Size, By Product Type, 2016-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.4.4.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.4.5.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.4.6.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.4.7.2 Market size, By Product Type, 2016-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.4.8.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2016-2026 (USD Million)
6.5.2 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.5.3 Market Size, By Product Type, 2016-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.5.4.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.5.5.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.5.6.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2016-2026 (USD Million)
6.6.2 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.6.3 Market Size, By Product Type, 2016-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.6.4.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.6.5.2 Market Size, By Product Type, 2016-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Therapeutic Approach, 2016-2026 (USD Million)
6.6.6.2 Market Size, By Product Type, 2016-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 Italfarmaco S.p.A.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info Graphic Analysis
7.3 FibroGen, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info Graphic Analysis
7.4 Summit Therapeutics Plc
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info Graphic Analysis
7.5 PTC Therapeutics
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info Graphic Analysis
7.6 Santhera Pharmaceuticals
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info Graphic Analysis
7.7 Sarepta Therapeutics, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info Graphic Analysis
7.8 NS Pharma, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info Graphic Analysis
7.9 Wave Life Sciences
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info Graphic Analysis
7.10 Daiichi Sankyo Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info Graphic Analysis
7.11 Pfizer Inc.
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info Graphic Analysis
7.12 Solid Biosciences
7.12.1 Company Overview
7.12.2 Financial Analysis
7.12.3 Strategic Positioning
7.12.4 Info Graphic Analysis
7.13 Other Companies
7.13.1 Company Overview
7.13.2 Financial Analysis
7.13.3 Strategic Positioning
7.13.4 Info Graphic Analysis
The Global Duchenne Muscular Dystrophy (DMD) Drugs Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Duchenne Muscular Dystrophy (DMD) Drugs Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
